Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eddie Darton
Observed names:
E Darton,
E. Darton
Institution:
Sarepta Therapeutics (United States)
Observed institution:
Sarepta Therapeutics (United States)
OpenAlex ID:
A5010795059
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
2024
·
Jerry R. Mendell
, Francesco Muntoni
, et al.
·
Nature Medicine
·
226
PDF
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP ‐9001‐103 ( ENDEAVOR )
2023
·
Craig M. Zaidman
, Crystal M. Proud
, et al.
·
Annals of Neurology
·
112
PDF
Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial
2023
·
Jerry R. Mendell
, Zarife Sahenk
, et al.
·
Muscle & Nerve
·
96
PDF
Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy
2024
·
Jerry R. Mendell
, Crystal Proud
, et al.
·
Pediatric Neurology
·
48
PDF
P.132 Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: Interim results from the Phase 3 ESSENCE trial
2022
·
S. Iannaccone
, H. Phan
, et al.
·
Neuromuscular Disorders
·
22
EMBARK, a Phase 3 Trial Evaluating Safety and Efficacy of Delandistrogene Moxeparvovec (SRP- 9001) in Duchenne Muscular Dystrophy (DMD): Study Design and Baseline Characteristics (P5-8.012)
2023
·
Francesco Muntoni
, Eugenio Mercuri
, et al.
·
Neurology
·
9
One-year Data from ENDEAVOR, a Phase 1b Trial of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD) (S48.003)
2023
·
Craig Zaidman
, Crystal Proud
, et al.
·
Neurology
·
3
Long-term Safety and Efficacy in Patients with DMD 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study (P3-8.006)
2023
·
Jerry Mendell
, Zarife Sahenk
, et al.
·
Neurology
·
3
P.134a Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update
2022
·
J. Mendell
, Z. Sahenk
, et al.
·
Neuromuscular Disorders
·
3
DMD - TREATMENT
2021
·
S. Iannaccone
, H. Phan
, et al.
·
Neuromuscular Disorders
·
3
P.128 Integrated analyses of data from clinical trials of delandistrogene moxeparvovec in DMD
2022
·
C. Zaidman
, P. Shieh
, et al.
·
Neuromuscular Disorders
·
2
P.129 One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD
2022
·
C. Zaidman
, C. Proud
, et al.
·
Neuromuscular Disorders
·
2
423P Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy: phase 3 EMBARK primary results
2024
·
J. Mendell
, F. Muntoni
, et al.
·
Neuromuscular Disorders
·
1
P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study*
2023
·
Erin O’Rourke
, Jerry R. Mendell
, et al.
·
Genetics in Medicine Open
·
1
PDF
Safety and Efficacy of Delandistrogene Moxeparvovec versus Placebo in Duchenne Muscular Dystrophy (EMBARK): Pivotal Phase 3 Primary Results
2024
·
I. Seelmann
, J. R. Mendell
, et al.
·
Neuropediatrics
D.4 Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results
2024
·
JR Mendell
, F Muntoni
, et al.
·
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
PDF
P42 Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy
2023
·
J. Mendell
, C. Proud
, et al.
·
Neuromuscular Disorders
P41 EMBARK, a Phase 3 trial evaluating safety and efficacy of delandistrogene moxeparvovec in DMD: study design and baseline characteristics
2023
·
F. Muntoni
, E. Mercuri
, et al.
·
Neuromuscular Disorders
Integrated Analyses of Data from Clinical Trials of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD) (S48.006)
2023
·
Crystal Proud
, Craig Zaidman
, et al.
·
Neurology
O19: Integrated analyses of data from clinical trials of delandistrogene moxeparvovec gene therapy in DMD*
2023
·
Erin O’Rourke
, Crystal Proud
, et al.
·
Genetics in Medicine Open
PDF
Show more works
View as search
Works count:
20
Citation count:
531
H-index:
6
I10-index:
5
Year
Topic
Type